CRISPR Therapeutics (CRSP) to Release Earnings on Tuesday

CRISPR Therapeutics (NASDAQ:CRSP) is expected to be posting its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect CRISPR Therapeutics to post earnings of ($1.32) per share and revenue of $8.7390 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 12:00 AM ET.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The business had revenue of $0.89 million for the quarter, compared to analyst estimates of $6.44 million. During the same period last year, the company earned ($1.49) EPS. The firm’s revenue was up 72.5% on a year-over-year basis. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Stock Down 2.8%

NASDAQ:CRSP opened at $65.72 on Tuesday. The firm has a market capitalization of $5.98 billion, a P/E ratio of -12.10 and a beta of 1.84. CRISPR Therapeutics has a 12-month low of $30.04 and a 12-month high of $78.48. The stock’s fifty day simple moving average is $61.78 and its 200-day simple moving average is $51.74.

Analyst Ratings Changes

Several analysts recently commented on the company. Wells Fargo & Company set a $75.00 price objective on CRISPR Therapeutics in a research note on Monday, October 13th. Zacks Research raised CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. JPMorgan Chase & Co. assumed coverage on CRISPR Therapeutics in a research note on Thursday, September 18th. They set an “overweight” rating and a $70.00 price objective on the stock. Royal Bank Of Canada raised their price objective on CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a “sector perform” rating in a research note on Tuesday, August 5th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, August 5th. Ten analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $72.59.

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,895 shares of CRISPR Therapeutics stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $67.91, for a total value of $3,456,279.45. Following the sale, the chief executive officer owned 254,201 shares of the company’s stock, valued at $17,262,789.91. This trade represents a 16.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the completion of the sale, the general counsel directly owned 83,402 shares in the company, valued at $5,554,573.20. This represents a 1.27% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 56,213 shares of company stock worth $3,810,458 in the last three months. Company insiders own 4.30% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Federated Hermes Inc. acquired a new stake in shares of CRISPR Therapeutics in the 2nd quarter valued at about $614,000. Sei Investments Co. acquired a new stake in shares of CRISPR Therapeutics in the second quarter valued at about $555,000. NewEdge Advisors LLC increased its position in shares of CRISPR Therapeutics by 154.4% in the second quarter. NewEdge Advisors LLC now owns 8,577 shares of the company’s stock valued at $417,000 after acquiring an additional 5,205 shares during the last quarter. Orion Porfolio Solutions LLC acquired a new stake in shares of CRISPR Therapeutics in the second quarter valued at about $395,000. Finally, Headlands Technologies LLC acquired a new stake in shares of CRISPR Therapeutics in the second quarter valued at about $394,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.